VON-WILLEBRAND-FACTOR AND FACTOR-XIII IN CHILDREN WITH HENOCH-SCHONLEIN PURPURA

被引：46

作者：

DEMATTIA, D ^{[1
]}

PENZA, R ^{[1
]}

GIORDANO, P ^{[1
]}

DELVECCHIO, GC ^{[1
]}

ACETO, G ^{[1
]}

ALTOMARE, M ^{[1
]}

SCHETTINI, F ^{[1
]}

机构：

[1] UNIV BARI,DIPARTIMENTO BIOMED ETA EVOLUT,PEDIAT CLIN 1,I-70124 BARI,ITALY

来源：

PEDIATRIC NEPHROLOGY | 1995年 / 9卷 / 05期

关键词：

FACTOR XIII; VON WILLEBRAND FACTOR; HENOCH-SCHONLEIN PURPURA; COAGULATION;

D O I：

10.1007/BF00860949

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Levels of von Willebrand factor antigen (vWf: Ag) and factor XIII activity (F XIII) were studied in relation to the severity of clinical symptoms (scored from 0 to 3) and to immunological parameters [IgA, C3, C4, and circulating immune complexes (CIC)] in 16 children (7 males, 9 females, aged 3-11 years) with Henoch-Schonlein purpura (HSP) at presentation. vWf:Ag was increased in 7 patients, F XIII activity was decreased in 6. In all children we found high levels of IgA, while C3 and C4 levels were normal; CIC were elevated in 11. vWf:Ag correlated with clinical score and with IgA and CIC, probably as a result of immune-mediated endothelial cell damage. The haemostatic alterations observed in HSP are important for understanding the pathophysiology of the disease.

引用

页码：603 / 605

页数：3

共 22 条

[1]

Blankship B.E., Henoch-Schonlein purpura: a review, J Tenn Med Assoc, 78, pp. 615-618, (1985)

[2]

Lanzkowsky S., Lanzkowsky L., Lanzkowsky P., Henoch-Schonlein purpura, Pediatr Rev, 13, pp. 130-137, (1992)

[3]

Barberio G., Manganaro R., Ruggeri C., Cambria R., Gattarello A., Gemelli M., Behaviour of clotting parameters in Schonlein-Henoch syndrome. Diagnostic value of factor XIII, Minerva Pediatr, 33, pp. 817-820, (1981)

[4]

Henriksson P., Hedner U., Nilsson I.M., Factor XIII (fibrin stabilizing factor) in Henoch-Schonlein purpura, Acta Paediatr Scand, 66, pp. 273-277, (1977)

[5]

Dalens B., Travade P., Labbe A., Bezou M.J., Diagnostic and prognostic value of fibrin stabilizing factor in Schonlein-Henoch syndrome, Arch Dis Child, 58, pp. 12-14, (1983)

[6]

Clark J.H., Fitzgerald J.F., Hemorrhagic complications of Henoch-Schonlein syndrome, J Pediatr Gastroenterol Nutr, 4, pp. 311-315, (1985)

[7]

Kamitsuji H., Tani K., Yasui M., Taniguchi A., Taira K., Tsukada S., Et al., Activity of blood coagulation factor XIII as a prognostic indicator in patients with Henoch-Schonlein purpura, Eur J Pediatr, 146, pp. 519-523, (1987)

[8]

Fukui H., Kamitsuji H., Nagao T., Yamada K., Akatsuka J., Inagaky M., Et al., Clinical evaluation of a pasteurized factor XIII concentrate administration in Henoch-Scholein purpura, Thromb Res, 56, pp. 667-675, (1989)

[9]

Rose P.E., Struhhers G.S., Robertson M., Kavi J., Chant I., Taylor C.M., Factor VIII von Willebrand protein in haemolytic uraemic syndrome and systemic vasculitides, Lancet, 1, pp. 500-502, (1990)

[10]

Ambruso D.R., Durante D.P., McIntosh R.M., Hathaway W.E., Factor VIII and renal disease, Ann Intern Med, 87, pp. 636-639, (1977)

← 1 2 3 →